Quantcast

Latest MedImmune Stories

2011-02-09 08:00:00

ROCKVILLE, Md., Feb. 9, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that Dr. Gregory Glenn, Chief Medical Officer of Novavax, will be presenting safety and immunogenicity data from its pivotal 2009 A/H1N1 virus-like particle (VLP) pandemic influenza vaccine clinical trial in Mexico, at the invitation-only 7th WHO Meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials. The meeting is being held February 17-18, 2011 at...

2011-02-08 07:44:00

-The Company launches the clinical development of its seasonal flu vaccine- QUEBEC CITY, Feb. 8 /PRNewswire-FirstCall/ - Medicago Inc. (TSX: MDG) a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced it has received Food and Drug Administration ("FDA") clearance for its phase I H1N1 influenza VLP vaccine candidate ("H1N1 vaccine") clinical trial in the...

2011-01-27 04:07:00

NEW YORK, Jan. 27, 2011 /PRNewswire/ -- Get content from AstraZeneca at: http://www.thenewsmarket.com/Releases/StoryDetailPage.aspx?GUID=0be570e4-bf68-4c0b-9777-4d22d679e195# Anglo-Swedish pharmaceutical company AstraZeneca announced that revenue for the full year was unchanged at constant exchange rates (CER) at $33,269 million. Strong revenue growth in markets outside the US (up 7% at CER) broadly offset the loss of more than $1.6 billion of revenue in the US from generic competition...

2011-01-27 01:47:00

LONDON, January 27, 2011 /PRNewswire-FirstCall/ -- AstraZeneca said its full-year results had outperformed guidance, with growth in emerging markets compensating for patent expiries and pricing pressures from Western governments. The company said a reallocation of resources had led to growth of 16 per cent in its emerging markets, led by China where sales broke through the $1bn mark for the first time. In an interview with http://www.cantos.com, David Brennan, CEO, said the...

2011-01-20 07:30:00

GAITHERSBURG, Md., Jan. 20, 2011 /PRNewswire/ -- MedImmune's Oncology group announced today preclinical results showing that MEDI-573, a targeted monoclonal antibody, broadly suppresses pathways that have been shown to play a critical role in the development and progression of many solid tumors. The study, published in the February 1 issue of Cancer Research (a journal of the American Association for Cancer Research), suggests that MEDI-573 inhibits multiple biological pathways related to...

2011-01-10 06:00:00

INCLINE VILLAGE, Nev., Jan. 10, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that on January 7, 2011, the United States District Court for the Northern District of California issued summary judgment order deciding certain issues favorably and other issues adversely to PDL in its litigation with MedImmune. PDL disagrees with certain aspects of the court's decisions which are adverse to the Company and is evaluating its legal options, including appeal of...

2011-01-07 09:28:00

GAITHERSBURG, Md., Jan. 7, 2011 /PRNewswire/ -- MedImmune today announced an in-licensing agreement with Amgen for a novel monoclonal antibody targeting the IL-1 pathway. The antibody, AMG 108, a fully human monoclonal antibody to the IL-1 receptor, has been studied in multiple phase 1 and phase 2 clinical trials and will now be explored by MedImmune for its potential against certain inflammatory diseases. Under the terms of the agreement, Amgen grants MedImmune rights to develop AMG...

2010-12-23 07:45:00

Successes Validate UMd.'s Entrepreneurship Ecosystem COLLEGE PARK, Md., Dec. 23, 2010 /PRNewswire-USNewswire/ -- Martek Biosciences, a company that launched leveraging the Maryland Technology Enterprise Institute (Mtech) at the University of Maryland, entered an agreement on December 21 to be acquired by the Dutch company Royal DSM NV for $1.1 billion, the companies jointly announced. (Logo: http://photos.prnewswire.com/prnh/20101005/MTECHLOGO) Martek is the second company sold for more...

2010-12-22 16:00:00

WILMINGTON, Del., Dec. 22, 2010 /PRNewswire/ -- AstraZeneca (NYSE: AZN) announced today that it has notified Abbott that it will discontinue the development of CERTRIAD(TM) (rosuvastatin calcium and fenofibric acid), which was being investigated for the treatment of mixed dyslipidemia. This means the co-development and license agreement with Abbott will end on January 22, 2011. A Complete Response Letter (CRL) for the CERTRIAD New Drug Application (NDA) was received from the U.S. Food...

2010-12-22 07:55:00

QUEBEC CITY, QC, Dec. 22 /PRNewswire/ - Medicago Inc. (TSX: MDG) a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that the last dose of vaccine has been administered completing the first part of the Company's Phase II human clinical trial with its H5N1 Avian Influenza vaccine ("H5N1 vaccine").  The Company expects to present interim Phase II...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'